In contrast, IKZF2 transactivation was enriched in CD30+ TMF, and IKZF2 has been reported to downregulate HLA type II genes in MF cells, which may help to CD30+ TMF cells escape the anti-tumor immunity (48). This evidence concerns the gene TNFRSF8 and neoplasm.